A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease.

• Main Authors: Akie eTanabe, Yukio eYamamura, Jiro eKasahara, Ryoma eMorigaki, Ryuji eKaji, Satoshi eGoto
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2014-02-01
• Series: Frontiers in Cellular Neuroscience
• Subjects: Cyclin-Dependent Kinase 5; Parkinson's disease; DARPP-32; CDK5; nilotinib; c-Abl inhibitor
• Online Access: http://journal.frontiersin.org/Journal/10.3389/fncel.2014.00050/full

Abnormal motor behaviors in Parkinson’s disease (PD) result from striatal dysfunction due to an imbalance between dopamine and glutamate transmissions that are integrated by dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32). c-Abelson tyrosine kinase (c-Abl) phosphorylates cyclin-dependent kinase 5 (Cdk5) at Tyr15 to increase the activity of Cdk5, which reduces the efficacy of dopaminergic signaling by phosphorylating DARPP-32 at Thr75 in the striatum. Here, we report that in the mouse striatum, a novel c-Abl inhibitor, nilotinib (AMN107), inhibits phosphorylation of both Cdk5 at Tyr15 and DARPP-32 at Thr75, which is negatively regulated by dopamine receptor activation through a D2 receptor-mediated mechanism. Like a D2-agonist, nilotinib synergizes with a D1-agonist for inducing striatal c-Fos expression. Moreover, systemic administration of nilotinib normalizes striatal motor behaviors in a mouse model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). These findings suggest that nilotinib could possibly serve as a new and alternative agent for treating PD motor symptoms.<br/><br/>